Campbell D.K. Rogers, M.D., is a renowned interventional cardiologist and healthcare leader serving as Chief Medical Officer at HeartFlow, Inc. He earned his medical degree from Duke University School of Medicine and completed his internal medicine residency and cardiology fellowship at Massachusetts General Hospital/Harvard Medical School. Dr. Rogers then joined the faculty at Brigham and Women's Hospital/Harvard Medical School, where he built an esteemed clinical practice, directed the cardiac catheterization laboratories, and conducted pioneering research in coronary interventions and restenosis prevention. Transitioning to industry leadership, Dr. Rogers held senior executive roles at Medtronic and Cordis Corporation (a Johnson & Johnson company), culminating as Worldwide President of Cardiovascular. There, he spearheaded the development and global launch of transformative technologies, including the CYPHER drug-eluting stent, which revolutionized treatment for coronary artery disease and reduced restenosis rates dramatically. His contributions include over 100 peer-reviewed publications, patents, and advisory roles with the FDA and major cardiology societies. At HeartFlow, Dr. Rogers drives the company's clinical, regulatory, and medical affairs strategies, advancing its AI-enabled, non-invasive platform for coronary plaque analysis and heart flow modeling—the first FDA-cleared such technology. Under his guidance, HeartFlow has expanded its impact through landmark trials like HEARTFLOW FFRct, improving diagnostic accuracy, reducing unnecessary procedures, and enhancing patient outcomes worldwide.